Sweden. Elekta AB

The loan has been provided to finance in part Elekta’s R&D investments during 2021–2025. The company develops state-of-the-art radiation therapy and radiosurgery tools, clinical treatment solutions and workflow enhancing software systems supporting the spectrum of cancer care.

Radiotherapy is one of the most important tools in cancer care, and approximately half of all patients are prescribed radiotherapy during the course of their treatment. Elekta’s R&D is targeting, amongst other areas, image-guided radiation therapy and stereotactic radiosurgery.

Part of the research will be carried out in Sweden, where Elekta is intensifying its R&D activities.

This is the second loan agreed with Elekta; the first was signed in 2017.

Elekta AB develops clinical solutions and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as medical software solutions. The company’s products are utilised in hospitals worldwide. Elekta is headquartered in Stockholm, Sweden, and employs around 4,000 people globally.

Productivity:

Elekta’s annual R&D investments account for approximately 10% of total net sales, and are expected to increase further in the coming years. The increasing R&D activities in Sweden add value to the product offering by integrating interdisciplinary activities and research, as well as cooperation with clinics and academic hospitals. These activities and cooperations are likely to include improved control of tumours, radiation dose calculation, radiation physics, software and deep learning. The research Elekta will conduct is likely to change the current standard of care for cancer patients by improving the precision of radiation delivery.

Environment:

The R&D activities are not assessed to have any significant environmental impact.

Indicators for the expected impact of the investment:

–        The company’s R&D intensity

–        R&D costs in Sweden during 2021–2025

No sustainability issues are expected to result from the project.